众生药业跌2.14%，成交额2.32亿元，主力资金净流出1034.48万元

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced fluctuations, with a year-to-date increase of 72.05%, but a recent decline of 3.56% over the last five trading days [1] Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical reported revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%, while net profit attributable to shareholders increased by 114.96% to 188 million yuan [2] - The company has distributed a total of 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Zhongsheng Pharmaceutical was 89,900, a decrease of 1.32% from the previous period, with an average of 8,470 circulating shares per shareholder, an increase of 1.33% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 9.1731 million shares, a new addition, while other significant shareholders have reduced their holdings [3] Market Activity - On September 3, 2023, Zhongsheng Pharmaceutical's stock price was 20.56 yuan per share, with a trading volume of 2.32 billion yuan and a turnover rate of 1.46% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 181 million yuan on July 29 [1] Business Overview - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals, with 96.13% of its revenue coming from pharmaceutical manufacturing [1]